Boundless Bio, Inc. (BOLD)
About Boundless Bio, Inc.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$58.2M
- Total assets
- $157.1M
- Market cap
- $31.9M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $63.6M
- Operating income
- -$63.6M
- Income tax
- $0
- Net income
- -$58.2M
- EPS (basic)
- $-2.60
- EPS (diluted)
- $-2.60
Balance sheet
- Total assets
- $157.1M
- Current assets
- $109.6M
- Total liabilities
- $58.4M
- Current liabilities
- $12.5M
- Shareholders’ equity
- $98.7M
Cash flow
- Operating cash flow
- -$46.7M
- Investing cash flow
- $37.8M
- Financing cash flow
- $141.0K
- Net cash flow
- -$8.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $31.9M
- EPS (diluted)
- $-2.6
- Shares outstanding
- 12.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 28, 2024
Boundless Bio, Inc. (BOLD) Stock Price
- Reported a net loss of $58.2M.
- Trading near its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Boundless Bio, Inc..
Write a review
News about Boundless Bio, Inc.
News & sentiment via Polygon.io
Boundless Bio, Inc.: frequently asked questions
Is Boundless Bio, Inc. an American company?
Boundless Bio, Inc. is a US-based company headquartered in San Diego, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Boundless Bio, Inc. headquartered?
Boundless Bio, Inc. is headquartered in San Diego, California, United States.
Is Boundless Bio, Inc. publicly traded?
Yes — Boundless Bio, Inc. is a publicly traded company. Its stock trades under the ticker symbol BOLD on the NASDAQ.
What does Boundless Bio, Inc. do?
Boundless Bio, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
